Ref. No.: NLL/CS/2026- 703 **August 14, 2026**

To,

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 532649

Sub: Outcome of Board Meeting

Ref.: Regulation 30 and 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulation").

Dear Sir/ Madam,

We wish to inform you that the board of directors of Nectar Lifesciences Limited ("Company") in their meeting held on August 14, 2026, have, inter-alia, noted, decided and approved the following matters:

1. The unaudited standalone and consolidated financial results for the quarter ended on June 30, 2026, which are enclosed herewith along with the limited review reports of the auditors thereon as **Annexure- A**;

2. Appointed Dr. Gunmala Suri (DIN: 11879344) as an Additional Director from August 15, 2026, till forthcoming Annual General meeting ("AGM") as well as Non-Executive Non-Independent Director subject to approval of members at the forthcoming AGM of the Company with effect from August 15, 2026;

The requisite details regarding appointment of Director required under the LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and as amended upto date, are provided in **Annexure- B**.

3. To convene the 31st AGM of the members of the Company on **Friday**, **September 18, 2026**;

4. To close the register of members and share transfer books from September 12, 2026, to September 18, 2026 (both days inclusive) for the purpose of AGM. Accordingly, the cut-off date, to ascertain the eligibility of members for remote e-voting and polling/ e-voting at AGM, is September 11, 2026, i.e., the date prior to the commencement of book closure;

5. The re-appointment of Mr. Sanjiv Goyal (DIN: 00002841), director, who retire by rotation, in the forthcoming AGM;

6. The proposal for appointment of Dr. Gunmala Suri (DIN: 11879344) as a regular director as well as Non-Executive Non-Independent Director with effect from August 15, 2026,

subject to approval of the members at the forthcoming AGM;

7. Reconstitution of the Audit Committee, Stakeholders Relationship Committee ("SRC") and Corporate Social Responsibility Committee ("CSR") w.e.f. August 14, 2026.

Post reconstitution, the composition of the committees are as under:

1. Audit Committee

S. No.	Name of Committee members	Position in Committee	Nature of Directorship
1.	Dr. Rupinder Tewari	Chairperson	Non-Executive Independent Director
2.	Dr. Indu Pal Kaur	Member	Non-Executive Independent Director
3.	Dr. Kuldip Kumar Bhasin	Member	Non-Executive Independent Director
4.	Mr. Sushil Kapoor	Member	Whole-time Director & Chief Financial Officer ("CFO")

2. SRC

S. No.	Name of Committee members	Position in Committee	Nature of Directorship
1.	Dr. Kuldip Kumar Bhasin	Chairperson	Non-Executive Independent Director
2.	Mr. Sanjiv Goyal	Member	Chairman & Managing Director
3.	Mr. Sushil Kapoor	Member	Whole-time Director & CFO

3. CSR

S. No.	Name of Committee members	Position in Committee	Nature of Directorship
1.	Dr. Kuldip Kumar Bhasin	Chairperson	Non-Executive Independent Director
2.	Mr. Sanjiv Goyal	Member	Chairman & Managing Director
3.	Mr. Sushil Kapoor	Member	Whole-time Director & CFO

The Board Meeting commenced at 07:30 P.M. IST and concluded at 08:35 P.M. IST.

Kindly take the same on record.

Thanking you,

Yours faithfully,
For **Nectar Lifesciences Limited**
Sanjaymohan Singh Rawat
Digitally signed by Sanjaymohan Singh Rawat
Date: 2026.08.14 20:42:42 +05'30'
(Sanjaymohan Singh Rawat)
Company Secretary & Compliance Officer

Annexure- A

NECTAR LIFESCIENCES LIMITED									
Regd.Office: Showroom no. 8, First Floor, Patiala Complex, Barwala Road, Dera Bassi, Distt. S.A.S Nagar, Punjab- 140 507, INDIA, Email : cs@neclife.com, Website : www.neclife.com, [CIN: L21000PB1995PLC016664]									
Statement of Financial Results for the Quarter ended 30.06.2026 (Rs in Lacs)									
S. No.	**Particulars**	**Standalone**				**Consolidated**			
		Quarter Ended			**Year Ended**	**Quarter Ended**			**Year Ended**
		30-Jun-26	**31-Mar-26**	**30-Jun-25**	**31-Mar-26**	**30-Jun-26**	**31-Mar-26**	**30-Jun-25**	**31-Mar-26**
		Unaudited	**Audited**	**Unaudited**	**Audited**	**Unaudited**	**Audited**	**Unaudited**	**Audited**
	Continuing Operations								
I	**Income from Operations**								
	Sales	1.45	-	-	-	1.45	-	-	-
	Other operating Income	42.76	128.97	0.63	201.05	42.76	128.97	0.63	201.05
II	Other Income	585.26	629.03	30.31	728.04	291.99	629.03	30.31	728.04
III	**Total Income (I + II)**	**629.47**	**758.00**	**30.94**	**929.09**	**336.20**	**758.00**	**30.94**	**929.09**
IV	**Expenses**								
	(a) Cost of Materials consumed	-	-	-	-	-	-	-	-
	(b) Purchase of Stock in Trade	2.75	-	-	-	2.75	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1.38)	-	-	-	(1.38)	-	-	-
	(d) Employee benefits expense	103.28	125.36	2.02	190.36	106.37	126.22	2.04	191.22
	(e) Finance costs	15.69	590.05	-	3,612.52	15.69	590.05	0.01	3,612.52
	(f) Depreciation and amortisation expense	11.06	8.28	8.71	34.26	11.06	8.28	8.66	34.26
	(g) Other expenses	2,663.56	5,726.27	6.68	5,878.94	2,663.66	5,726.31	6.69	5,878.98
	Total Expenses (IV)	**2,794.96**	**6,449.96**	**17.41**	**9,716.08**	**2,798.15**	**6,450.86**	**17.40**	**9,716.98**
V	**Profit/(Loss) before exceptional items and tax from continuing operations (III- IV)**	**(2,165.49)**	**(5,691.96)**	**13.53**	**(8,786.99)**	**(2,461.95)**	**(5,692.86)**	**13.54**	**(8,787.89)**
VI	Exceptional item	-	-	-	-	-	-	-	-
VII	**Profit/(Loss) before from continuing operations (V- VI)**	**(2,165.49)**	**(5,691.96)**	**13.53**	**(8,786.99)**	**(2,461.95)**	**(5,692.86)**	**13.54**	**(8,787.89)**
VIII	**Tax Expense of continuing operations**								
	Current Tax	-	-	-	-	-	-	-	-
	Deferred Tax	(819.87)	(1,971.36)	4.73	(3,052.88)	(890.08)	(1,971.64)	4.73	(3,053.16)
IX	**Profit for the period from continuing operations (VII-VIII)**	**(1,345.62)**	**(3,720.60)**	**8.80**	**(5,734.11)**	**(1,571.87)**	**(3,721.22)**	**8.81**	**(5,734.73)**
	Discontinued Operations								
	Profit before tax from discontinued operations	49.35	(7,320.58)	(9,688.97)	(53,765.51)	49.35	(7,320.58)	(9,688.97)	(53,765.51)
	Exceptional item (Gain on slump sale)	-	-	-	16,337.32	-	-	-	16,337.32
	Tax expenses of discontinued operations	17.25	(4,249.38)	(3,357.08)	(13,873.82)	17.25	(4,249.38)	(3,357.08)	(13,873.82)
	Profit for the period from discontinued operations	**32.10**	**(3,071.20)**	**(6,331.89)**	**(23,554.37)**	**32.10**	**(3,071.20)**	**(6,331.89)**	**(23,554.37)**
	Total Profit for the period	**(1,313.52)**	**(6,791.80)**	**(6,323.09)**	**(29,288.48)**	**(1,539.77)**	**(6,792.42)**	**(6,323.08)**	**(29,289.10)**
	Other Comprehensive Income								
	Items that will not be reclassified subsequently to profit or loss								
	Remeasurement of the net defined benefit liability/asset	-	12.18	-	12.18	-	12.18	-	12.18
	Income Tax relating to items that will not be reclassified to profit or loss	-	(4.26)	-	(4.26)	-	(4.26)	-	(4.26)
	Items that will be reclassified subsequently to profit or loss								
	Foreign Exchange Translation Reserve (Net of Tax)	-	-	-	-	-	0.02	0.01	0.03
	Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	(0.01)	-	(0.01)
	Total Other Comprehensive Income, (Net of Tax)	**-**	**7.92**	**-**	**7.92**	**-**	**7.93**	**0.01**	**7.94**
	Total Comprehensive Income for the period	**(1,313.52)**	**(6,783.88)**	**(6,323.09)**	**(29,280.56)**	**(1,539.77)**	**(6,784.49)**	**(6,323.07)**	**(29,281.16)**
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up) (before and after exceptional item)								
	a) Basic continuing operations (In Rs.)	(0.69)	(1.85)	-	(2.62)	(0.81)	(1.85)	-	(2.62)
	b) Diluted continuing operations (In Rs.)	(0.69)	(1.85)	-	(2.62)	(0.81)	(1.85)	-	(2.62)
	c) Basic discontinued operations (In Rs.)	0.02	(1.53)	(2.82)	(10.78)	0.02	(1.53)	(2.82)	(10.78)
	d) Diluted discontinued operations (In Rs.)	0.02	(1.53)	(2.82)	(10.78)	0.02	(1.53)	(2.82)	(10.78)
	e) Basic continuing & discontinued operations (In Rs.)	(0.68)	(3.38)	(2.82)	(13.40)	(0.79)	(3.38)	(2.82)	(13.40)
	f) Diluted continuing & discontinued operations (In Rs.)	(0.68)	(3.38)	(2.82)	(13.40)	(0.79)	(3.38)	(2.82)	(13.40)

<u>Notes</u>

1. The above financial results were reviewed by Audit Committee on August 14, 2026, and approved by the Board in its meeting held on August 14, 2026. The statutory auditors of the Company have conducted a "Limited Review" of the above standalone and consolidated unaudited financial results for the quarter ended on June 30, 2026.

2. The Company is exclusively in the pharmaceutical business segment.

3. Previous period's figures have been regrouped and reclassified wherever necessary to make them comparable with current period.

4. The figures of the last quarter for the previous financial year i.e. March 31, 2026, are the balancing figures between the audited figure in respect of the full previous financial year ended March 31, 2026, and the unaudited published year to date figures up to the third quarter ended December 31, 2025, which was subject to limited review and not audit.

5. The Company has two wholly owned subsidiaries with the following details: -

   a) Neclife PT, Unipessoal LDA, remained inoperative during the period.

   b) Avensis Exports Private Limited ("AEPL").

6. The Company is "**Not a Large Corporate**" as per the framework provided in the SEBI Circular dated October 19, 2023, on Fund raising by issuance of debt securities by Large Entities.

7. **Going Concern**
   During the previous financial year, the Company had sold a substantial part of its existing business operations by way of slump sale and incurred losses. The transaction had resulted in significant liquidity, and the Company, after discharging all its debts, continues to possess adequate cash and liquid resources to meet its obligations, if any. Further, the Company had amended its object clause to undertake activities in the real estate sector and is currently evaluating the various projects under the revised business framework. In furtherance of this objective, the Company had also acquired AEPL as its wholly owned subsidiary. Considering the Company's solvent financial position and availability of funds, the Board believes that the Company will continue to operate as a going concern for the foreseeable future. Accordingly, the financial results have been prepared on a going concern basis.

8. **Material Transactions**

   A. Assets Classified as Held for Sale

   a. Capsule Business (EHGC)
   The Company had entered into a Business Transfer Agreement ("Capsule BTA") dated December 20, 2025, with Capnest Health Care Private Limited ("Capnest") for the slump sale of its Empty Hard Gelatin Capsule business located at Village Bhatoli Kalan, Pargana Dharmpur, Tehsil Baddi, District Solan, Himachal Pradesh ("Capsule Business"), on a going concern basis, for a consideration of ₹1,990.00 lakhs, including transfer of related receivables and payables/creditors, subject to working capital adjustments specified in

the Capsule BTA and approval under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act, 1972. The transaction shall be completed in accordance with the terms set out in the Capsule BTA.

b. Other Assets

The Company is also evaluating the monetization of the following assets with the objective of optimizing non-core assets and further strengthening its liquidity position:

(i) **Jammu Unit**: Fixed assets pertaining to the Company's Jammu unit, which has remained inoperative. The same has been disposed of in the subsequent quarter, and the impact thereof will be disclosed accordingly.

(ii) **Land near Garhshankar, Punjab**: Vacant land situated near Garhshankar, Punjab. A portion of the said land has already been sold in the current quarter, and the balance is expected to be sold by the end of this financial year.

Accordingly, the results relating to the above disposed businesses/assets have been disclosed as discontinued operations in accordance with Ind AS 105.

Further, in the audited standalone financial results, the net result of "Capsule Business" has been disclosed separately as discontinued operation as required by Indian Accounting Standard (Ind AS) 105 – *Asset Held for Sale and Discontinued Operations* and Schedule III to the Companies Act, 2013. Consequently, the Company's Statement of Profit and Loss for the period ended June 30, 2026, pertains to its continuing operations only and for that purpose the results for the other reporting periods i.e., March 31, 2026, and June 30, 2025, have been restated accordingly.

Standalone Operations relating to the "Capsule Business" in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below:

₹ in lakhs

S. No.	Particulars	Quarter Ended			Year Ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
				Restated	
		Unaudited	Audited	Unaudited	Audited
1	Revenue from operations	574.14	571.35	28,066.50	40,138.43
2	Other income	5.45	0.18	4.68	1,221.82
3	Total expenses	530.24	7,892.12	37,760.15	95,125.77
4	**Profit before tax**	**49.35**	**(7,320.59)**	**(9,688.97)**	**(53,765.51)**
5	Exceptional item (Gain on slump sale)	-	-	-	16,337.32
6	Tax expenses	17.25	(4,249.39)	(3,357.08)	(13,873.82)
7	**Net profit after tax**	**32.10**	**(3,071.20)**	**(6,331.89)**	**(23,554.37)**

9. Pursuant to the approvals granted by the Board, the Company deployed certain surplus funds in mutual fund, ETF and equity instruments during the year. Subsequently, volatility in the financial markets arising from prevailing market conditions and geopolitical developments adversely impacted the value of such investments, resulting in a loss of ₹2,513.29 lakhs. The resultant impact has been recognized in the Statement of Profit and Loss in accordance with Ind AS 109 – Financial Instruments.

By Order of the Board of Directors
of Nectar Lifesciences Limited

KANAV KAUSHAL Digitally signed by KANAV KAUSHAL Date: 2026.08.14 20:28:21 +05'30'

Sanjiv Goyal Digitally signed by Sanjiv Goyal Date: 2026.08.14 20:20:24 +05'30'

Date: 14.08.2026
Place: Sao Paulo, Brazil

(Sanjiv Goyal)
Chairman & Managing Director

Independent Auditor's review report on the Quarterly Unaudited Standalone Financial Results of the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of,
Nectar Lifesciences Limited,
Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Nectar Lifesciences Limited ("the Company") for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial

DEEPAK JINDAL & CO.
CHARTERED ACCOUNTANTS
FRN023023N
CHANDIGARH

data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms. of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Deepak Jindal & Co.
Chartered Accountants
Firm Regn. No. 023023N

DEEPAK JINDAL & CO
CHARTERED ACCOUNTANTS
FRN023023N
CHANDIGARH

(Kanav Kaushal)
Partner
M. No. 517148
UDIN: 26517148FQFOCH7507

Date: 14th Aug 2026
Place: Chandigarh

Independent Auditors' review report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended

To
The Board of Directors
Nectar Lifesciences Limited
Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Nectar Lifesciences Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been compiled from the related consolidated financial statements and been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial & accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

DEEPAK JINDAL & CO
CHARTERED ACCOUNTANTS
FRN023023N
CHANDIGARH

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the subsidiaries listed as below: -
   a. NECLIFE PT, UNIPESSOAL LDA (Inoperative)
   b. AVENSIS EXPORTS PRIVATE LIMITED

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the matter in which it is to be disclosed, or that it contains any material misstatement.

6. The unaudited consolidated financial results include the unaudited interim financial information of the subsidiary which have not been reviewed by their auditors, whose interim financial information excluding consolidation eliminations reflects total revenue of Nil, total net loss after tax of Rs. 226.24 million, total comprehensive loss of Rs. 226.24 million for the quarter ended June 30, 2026, as considered in the Statement. The unaudited financial information has been approved and furnished to us by the management. Our conclusion in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited financial information. According to the information and explanations given to us by management, this interim financial information's are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the management.

For Deepak Jindal & Co.
Chartered Accountants
Firm Regn. No. 023023N

DEEPAK JINDAL & CO
CHARTERED ACCOUNTANTS
FRN023023N
CHANDIGARH

(Kanav Kaushal)
Partner
M. No. 517148
UDIN: 26517148GKIJYP3432

Date: 14th Aug 2026
Place: Chandigarh

Annexure- B

Details as required as per LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and as amended upto date, are as follows:

Sr. No.	Particulars	Disclosures
		Dr. Gunmala Suri
1.	Reason for change viz. ~~Appointment, re- appointment,~~ resignation, ~~removal, death or otherwise~~	Appointed as an Additional Director in the category of Non-Executive Non-Independent Director, subject to approval of the shareholders.
2.	Date of appointment~~/re-appointment/ cessation (as applicable)~~ & term of appointment~~/ re- appointment~~	Additional Director with effect from August 15, 2026, till forthcoming AGM as well as Non-Executive Non-Independent Director subject to approval of members at the forthcoming Annual General meeting ("AGM") of the Company with effect from August 15, 2026.
3.	Brief profile (in case of appointment)	Dr. Gunmala Suri is a Professor at the University Business School, Panjab University, Chandigarh, with over 27 years of experience in teaching, research, academic administration, and industry–academia engagement. She holds a Ph.D. in Management from Agra University and an M.Sc. in Statistics from Gorakhpur University. She is the recipient of many prestigious awards such as Legendary Woman of the Decade by Women's Indian Chamber of Commerce and Industry, 2026 and Dewang Mehta National Education Award for Women in Education Leadership (2017). Her international academic exposure includes serving as a Visiting Fellow in Hungary under University Grants Commission (UGC), India award (2010), receiving the Indo-Swiss Bilateral Programme Fellowship (2007), and serving as a Visiting Fellow at the University of Lausanne, Switzerland (2005). She was also awarded the Commonwealth Fellowship (2003). She has published more than 100 research papers in reputed national and international journals and has written/contributed to 10 academic books and 6 research projects. Dr. Suri has guided and supervised research scholars and has been actively

		involved in Ph.D. evaluation, academic audits, curriculum development, quality assurance, and academic leadership. She has undertaken and executed consultancy and industry-based projects aimed at improving organizational efficiency, productivity, process effectiveness, and managerial performance, with a focus on applying management and analytical tools to address real-world organizational challenges. Dr. Suri has held several distinguished academic and professional positions. She has been a Member of the Governing Body of Sri Aurobindo College of Commerce, Ludhiana (2025) and is currently serving as Chairperson of the Indian Society for Training and Development (ISTD), Chandigarh Chapter, since 2018.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable ("NA")
5.	Certification of Director/ KMP/ Senior Management as per BSE Circular no. LIST/COMP/14/2018-19 and the NSE Circular no. NSE/ CML/2018/24, both dated 20 June 2018	NA
6.	Shareholding in the Company	NA
7.	Certification of Criteria of Independence in case of Independent Director	NA
8.	Letter of Resignation along with detailed reasons for resignation	NA
9.	Names of listed entities in which the resigning independent director holds directorships, indicating the category of directorship and membership of board committees, if an	NA
10.	Confirmation from Independent Director that there are no other material reasons of resignation other than those provided	NA